PIPELINE OF OUR WORK

Lacto Therapeuticals is working on a drug that will be effective in the treatment of toxic reactions to chemotherapy and radiation therapy, accompanied by activation of lipid peroxidation, parenchymatous jaundice with hyperbilirubinemia (in the absence of a mechanical factor in its development).

The drug:

• inhibits the formation of lipid peroxidation products in vitro and in vivo, exhibiting an antioxidant effect;

• prevents the development of nephro-hepato- and hematotoxicity in the induced toxicosis model, exhibiting a detoxifying effect;

• increases the latent period of occurrence of malignant tumors in the model of chemically induced carcinogenesis, reduces the frequency and rate of their development, exhibiting an anticarcinogenic effect.

• on museum strains of Pseudomonas aeruginosa it suppresses the growth of bacterial culture, exhibiting an antibacterial effect;

• is a non-toxic drug;

• does not stimulate the growth of transplantable tumors of various histogenesis in animals.

Lactoferrin appliance

Drug specifications

The drug will have high efficiency as an antioxidant with detoxifying, antibacterial, immunomodulatory properties and is well tolerated, and will have good prospects for inclusion in a complex of intensive care agents for conditions associated with entoxemia and multiple organ failure syndrome.

LF properties

The antioxidant, detoxifying and antibacterial properties of the drug against a number of pathogenic organisms involved in the development of nosocomial and opportunistic infections will serve as the basis for studying the effectiveness of the drug as a promising drug for the correction of oxidative stress, endotoxemia (mainly hepatic with hyperbilirubinemia) in patients with postoperative purulent-septic complications.

The development of purulent-septic complications in the postoperative period is accompanied by a sharp activation of lipid peroxidation, a decrease (up to depletion) in the functional activity of the antioxidant link of the detoxification system (i.e. the development of oxidative stress), suppression of the lymphocytic link of the immune system, and the occurrence of multiple organ failure against the background of endogenous toxemia.

These phenomena persist even after surgical sanitation of the purulent focus.

How LF works?

Inclusion of a highly active antioxidant drug in the intensive care regimen for purulent-septic postoperative complications, in the case of adequate surgical sanitation of the purulent focus, has a significant restorative effect on the body's antioxidant defense system, leading to a decrease in the initially high intensity of oxidative processes, promotes the resolution of secondary multiple organ failure, primarily liver failure, regression of purulent-inflammatory processes and endotoxemia, a clear tendency to normalize the lymphocytic link of the immune system.

This drug is safe and its use in patients in critical conditions will not be accompanied by intolerance or any other complications.